Literature DB >> 25761946

The Parkinson Disease Mitochondrial Hypothesis: Where Are We at?

Sandra Franco-Iborra1, Miquel Vila2, Celine Perier3.   

Abstract

Parkinson's disease is a common, adult-onset neurodegenerative disorder whose pathogenesis is still under intense investigation. Substantial evidence from postmortem human brain tissue, genetic- and toxin-induced animal and cellular models indicates that mitochondrial dysfunction plays a central role in the pathophysiology of the disease. This review discusses our current understanding of Parkinson's disease-related mitochondrial dysfunction, including bioenergetic defects, mitochondrial DNA alterations, altered mitochondrial dynamics, activation of mitochondrial-dependent programmed cell death, and perturbations in mitochondrial tethering to the endoplasmic reticulum. Whether a primary or secondary event, mitochondrial dysfunction holds promise as a potential therapeutic target to halt the progression of neurodegeneration in Parkinson's disease.
© The Author(s) 2015.

Entities:  

Keywords:  apoptosis; complex I; fusion/fission; mitochondria-associated endoplasmic reticulum membranes; mtDNA

Mesh:

Substances:

Year:  2015        PMID: 25761946     DOI: 10.1177/1073858415574600

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  56 in total

Review 1.  Parkinson's disease as a multisystem disorder.

Authors:  Lisa Klingelhoefer; H Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2017-02-02       Impact factor: 3.575

Review 2.  The c-Abl inhibitor in Parkinson disease.

Authors:  Zhi-Hua Zhou; Yun-Fan Wu; Xue-Min Wang; Yong-Zhu Han
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

3.  Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes.

Authors:  Lei Xia; Dianxuan Guo; Bing Chen
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

Review 4.  Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease.

Authors:  Nadee Nissanka; Carlos T Moraes
Journal:  FEBS Lett       Date:  2018-01-09       Impact factor: 4.124

Review 5.  Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neuromolecular Med       Date:  2018-03-23       Impact factor: 3.843

6.  Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.

Authors:  Danúbia Bonfanti Santos; Dirleise Colle; Eduardo Luiz Gasnhar Moreira; Mariana Appel Hort; Marcelo Godoi; Gael Le Douaron; Antonio Luiz Braga; Jamil Assreuy; Patrick Pierre Michel; Rui Daniel Prediger; Rita Raisman-Vozari; Marcelo Farina
Journal:  Mol Neurobiol       Date:  2016-02-06       Impact factor: 5.590

7.  A validated active contour method driven by parabolic arc model for detection and segmentation of mitochondria.

Authors:  Serdar F Tasel; Erkan U Mumcuoglu; Reza Z Hassanpour; Guy Perkins
Journal:  J Struct Biol       Date:  2016-03-05       Impact factor: 2.867

Review 8.  Parkinson's disease: experimental models and reality.

Authors:  Peizhou Jiang; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2017-11-18       Impact factor: 17.088

9.  α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton.

Authors:  Dalila G Ordonez; Michael K Lee; Mel B Feany
Journal:  Neuron       Date:  2017-12-14       Impact factor: 17.173

Review 10.  Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots.

Authors:  Shao-Hua Yang; Wenjun Li; Nathalie Sumien; Michael Forster; James W Simpkins; Ran Liu
Journal:  Prog Neurobiol       Date:  2015-11-18       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.